Latest News

Hetronifly is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody that has already received regulatory approval in China for treating several solid tumor types.

Once the transaction successfully closes, the combined company plans to operate under the PrimeGen US name or through a successor entity.

Visitors will explore the latest advancements to improve patient outcomes and operational efficiency through integrated clinical pathways that demonstrate a connected approach from early detection through treatment.

Attendees will include health ministers, government strategists, chief executive officers, international investors, and influential figures from artificial intelligence, digital health, and academic institutions.

Within the context of AI and automation, these leaders anticipate emerging technologies, design future workflows, and guide laboratories toward digital maturity through strategic vision.

Health authorities expect the vaccination programme to commence in 2026, marking a significant expansion of the country’s cervical cancer prevention efforts.

It encompasses the capacity to develop, manufacture, and discover through strong partnerships among government, academia, industry, and regulatory bodies.

The collaboration enables Sidra Medicine to connect Builders VC’s expertise and extensive network with their clinical teams, patient populations, and technological platforms.

The company plans to utilize two key facilities for this production: its Oxford, United Kingdom site and its Durham, North Carolina location.

The facility houses sophisticated laser systems, high-resolution imaging technology for examining the retina and optic nerve, and fully equipped operating theaters that adhere to the most stringent safety and quality standards.